News

Bioseutica's latest news

Lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19

Coronavirus disease 2019 (COVID-19), caused by SARS coronavirus 2 (SARS-CoV-2), is spreading rapidly with no established effective treatments.

Bioseutica statement on the COVID-19 outbreak

Zeewolde, March 28, 2020

The COVID-19 pandemic worries us all.

Bioseutica® co-founds Healiva®

We are excited to announce Healiva SA, an innovative startup venture in Lugano, Switzerland co-founded by Bioseutica BV.

Health Canada GMP inspection
In August 2018 Neova Technologies Inc. (NTI), a Bioseutica Group company had an inspection by Health Canada and received a compliance rating indicating that the activities inspected met the requirements outlined in the Canadian Food & Drug Act and its associated regulations.
Job Opportunity - Regulatory Affairs Specialist - Zeewolde The Netherlands

Bioseutica looking for an experienced Regulatory Affairs Specialist in food/feed worldwide.

Ovotransferrin as a novel drug-targeting molecule for cancer chemotherapy

In spite of the numerous discoveries of new anticancer drugs that work on different intracellular targets, many of these drugs have a considerable drawback as they are nonselective thus causing adv

Raising the bar of quality excellence

Our food production plant in Zeewolde (NL) has been inspected by FDA in October 2019, in accordance with “Preventive Controls and  Sanitary Human Food Operations-7303.040 Domestic and Imported Nutr

Trypsin VI and SE - EFSA scientific opinions

BIOSEUTICA is proud to inform that the European Food Safety Authority (EFSA) has just issued its scientific opinions on two applications submitted by NEOVA Technologies Inc (a  BIOSEUTICA grou